OraSure Technologies, Inc. (OSUR) News
Filter OSUR News Items
OSUR News Results
|Loading, please wait...|
OSUR News Highlights
- For OSUR, its 30 day story count is now at 7.
- Over the past 23 days, the trend for OSUR's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about OSUR are DRUG.
Latest OSUR News From Around the Web
Below are the latest news stories about Orasure Technologies Inc that investors may wish to consider to help them evaluate OSUR as an investment opportunity.
Total 2021 revenue of $233.7 million, up 36% year-over year InteliSwab® receives emergency use authorization expansion and demonstrates accurate detection of Omicron variant InteliSwab® revenue of $14.7 million in Q4, up 92% sequentially Management to Host Analyst/Investor Call and Webcast Today at 5:00 p.m. ET BETHLEHEM, Pa., Feb. 23, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbio
OraSure Technologies, Inc. 2021 Fourth Quarter Earnings Conference Call Wednesday, February 23, 2022, 5:00 p.m. ET
BETHLEHEM, Pa., Feb. 16, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 fourth quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Wednesday, February 23, 2022.
OraSure Technologies has filed for a $300M mixed shelf offering.
InteliSwab® COVID-19 Rapid Tests Receive U.S. FDA Authorization for Pediatric Use and Company Launches New InteliSwab® Connect Reporting App
Data Demonstrates InteliSwab ® is Accurate, Easy to Use, and Well Accepted by Children BETHLEHEM, Pa., Jan. 31, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR ), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that its InteliSwab ® COVID-19 rapid tests have been authorized by the U.S. Food and Drug Administration (FDA) for use in children ages 2 to 14. InteliSwab ® was previously authorized for use in adults and in children 15 to 17 when administered by an adult. As part of its submission to the FDA for this label expansion, the Company conducted studies to evaluate the performance of the test in a pediatric population, as well as studies to evaluate usability and tolerability by children. From a combine...
Shares of OraSure Technologies Inc. gained 2.2% in premarket trading on Monday after the company said its COVID-19 rapid tests have now been authorized for children between the ages of 2 and 14 years old. The tests had previously received emergency use authorization from the Food and Drug Administration for use in teens and adults. OraSure's stock is down 43.0% over the past year, while the broader S&P 500 is up 18.7%.
BETHLEHEM, Pa., Jan. 25, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that it has launched its OraQuick® HIV Self-Test, an oral swab in-home test for HIV-1 and HIV-2, into Europe. The test will be available in six European countries: United Kingdom, Germany, France, Italy, Spain and Portugal. “We are currently seeing an increase in HIV testing policies, as well
OraSure Technologies (NASDAQ:OSUR) shareholders have endured a 36% loss from investing in the stock a year ago
It's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly...
Hallstead, PA, based Investment company Peoples Financial Services Corp. (Current Portfolio) buys Danaher Corp, Goldman Sachs Group Inc, Thermo Fisher Scientific Inc, Vanguard Small Cap ETF, Kyndryl Holdings Inc, sells NBT Bancorp Inc, U.S.
InteliSwab test With less than one minute of “hands-on time,” the InteliSwab test is as simple as “Swab, Swirl, and See.” BETHLEHEM, Pa., Jan. 13, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that its InteliSwab® COVID-19 rapid tests detect the Omicron variant as effectively as they detect the original SARS-CoV-2 strain and other previous variants of concern, in
Tang previously spent more than a decade as president and CEO if the University City Science Center in Philadelphia.